Key Insights for Improving Adoption of Dual and Concurrent Testing for Cancer Care
An expert discusses how education about the clinical impact of genomic testing, understanding of targeted therapies, turnaround times, and team-based approaches are essential to bridge the gap in routine comprehensive genomic profiling adoption.
EP: 1.Comprehensive Genomic Profiling Is a Cornerstone of Cancer Care
EP: 2.Putting Comprehensive Genomic Profiling into Practice With Advanced Lung Cancer
EP: 3.Clinical Impact and Perspectives on Comprehensive Genomic Profiling in Advanced Lung Cancer Management
EP: 4.Key Insights for Improving Adoption of Dual and Concurrent Testing for Cancer Care
EP: 5.What’s Next for Comprehensive Genomic Profiling in Cancer Care
Video content above is prompted by the following:
Despite increasing adoption, significant gaps remain in routine comprehensive genomic profiling implementation. Education represents a core element in bridging these gaps, particularly regarding the clinical impact and value of identifying driver events for treatment selection. Clinicians need better understanding of both the testing technologies and the downstream therapeutic options available for patients with specific molecular profiles, creating a comprehensive educational approach that links diagnostic capabilities with treatment opportunities.
Enhanced education about turnaround times and behind-the-scenes testing activities helps clinicians better communicate with patients about result timelines and manage expectations effectively. Understanding the complexity of genomic testing processes enables better patient communication and workflow planning. This knowledge also helps clinical teams optimize their processes to minimize delays and ensure efficient test completion.
Successful implementation requires a multidisciplinary team approach where all health care team members understand the importance of genomic test results. Streamlined workflows and optimized processes are essential for decreasing time to results and ensuring test findings are easily visible and accessible to the entire care team. Strategies focus on providing targeted education within teams about genomic testing value and developing efficient workflows for rapid, comprehensive testing completion.
NCCN Guideline Updates in HR+ Breast Cancer: Focus on Extended Adjuvant Therapy
August 17th 2021This article reviews NCCN Guideline updates regarding the use of genomic assays in predicting the benefit of extended adjuvant endocrine therapy in patients with HR+ breast cancer and includes insights from Lee S. Schwartzberg, MD, of West Cancer Center at the University of Tennessee Health Science Center in Memphis, TN.
Prolaris in Practice: Guiding ADT Benefits, Clinical Application, and Expert Insights From ACRO 2025
April 15th 2025Steven E. Finkelstein, MD, DABR, FACRO discuses how Prolaris distinguishes itself from other genomic biomarker platforms by providing uniquely actionable clinical information that quantifies the absolute benefit of androgen deprivation therapy when added to radiation therapy, offering clinicians a more precise tool for personalizing prostate cancer treatment strategies.
Advances in Later-Line Management of Relapsed/Refractory Follicular Lymphoma
May 27th 2021This article reviews advances in later-line management of relapsed/refractory follicular lymphoma. This article also features insights from oncology expert Sameh Gaballa, MD, of Moffitt Cancer Center in Tampa, Florida.
